news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

reporter: zhao yangge

reporter: zhao yangge

last week, there were not many companies scheduled to attend the meeting, and one was rejected and one was postponed. at the same time, another six companies "quietly" withdrew their applications and withdrew from the front line. in the first week of september, the shanghai, shenzhen and beijing listing committees did not have any new meetings scheduled. will they enter a "resting period" again?

calabash brothers convertible bonds rejectedsource: exchange

the convertible bond project of huluwa (605199.sh), which was rejected last week, originally planned to raise 500 million yuan.

according to the data, huluwa was established in 2005 and listed on july 10, 2020.traditional chinese medicine and chemical medicine, such as xiaoer feire kechuan granules, compound isatis root granules, keke tablets, changyanning granules, changyanning capsules, omeprazole enteric-coated capsules, and cefixime dispersible tablets. data shows that huluwa's operating income in 2023 was 1.905 billion yuan, a year-on-year increase of 25.75%, and its net profit was 106 million yuan, a year-on-year increase of 24.29%; in the first half of 2024, its operating income was 847 million yuan, a year-on-year decrease of 7.36%, and its net profit was 78.7516 million yuan, a year-on-year increase of 28.33%.

its sponsor, cicc, plans to invest 250 million yuan in the "nanning production base phase ii project", 100 million yuan in the "digital construction project", and 150 million yuan in "supplementary working capital".